Vigonvita shares rocketed 185% on HK market debut.

The biopharmaceutical company offered 17.6 million H-shares in the global offering.

The Hong Kong public offer was 6,238.42 times oversubscribed, with a final allocation of 1.76 million shares, or 10% of the total offering.

The international offering was 16.87 times subscribed, with a final allocation of 15.8 million shares, or 90% of the total.